Of all the things Aurora Cannabis (ACB.T) does, sells, has bought, has planned, one stands out above all others as being their single most profitable business yet: Their investment in Green Organic Dutchman (TGOD.T).

A quarter billion in profit so far, that piece of good business far outweighs the returns on growing, processing, and selling medical cannabis.

In today’s Equity.Guru livestream interview on Twitch, we talk to ACB’s CCO, Cam Battley, who also sits on TGOD’s board, about how those companies found each other, what went down when ACB realized Organigram (OGI.V) had sold them tainted weed, the justification for buying Cannimed (CMED.T) at January prices in April, and much much more.

I haven’t always been too easy on Aurora, so I had a few prickly questions loaded up, and left feeling like most of them had been well answered.

Battley told us he had half an hour to chat. We kept him for nearly twice that, and could have gone another hour beyond.

Enjoy.

Watch Equity.Guru: Market Talk every Tues-thurs 1pm Pacific from EquityDotGuru on www.twitch.tv

— Chris Parry
FULL DISCLOSURE: TGOD is an Equity.Guru marketing client and the author owns stock and warrants in the company.

Written By:

Chris Parry

A multi-Webster Award winner for excellence in BC journalism, Parry is the founder and publisher of Equity.Guru, which he built with the specific plan to blend old school reporting with stock promotion, in a way that puts the emphasis on truth, high standards, and ethics. Parry is a veteran of TV, radio, and print, and consults with public companies to help them figure out their storylines, lay down achievable milestones, and improve their communication with shareholders, while also posting regular deep dive analysis of companies in the public spotlight.

More By This Author
Tags:
Cannabis
CBDs
Edibles
Growing
Livestreams
Parry
Series
ACB.T
Aurora Cannabis
CanniMed
CMED.T
Green Organic Dutchman
Livestreams
Medical marijuana
TGOD.T
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments